Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma

Transfusion

Volumn 49, Issue 9, 2009, Pages 1890-1900

  Yoon, Dok Hyun ^a   Sohn, Byeong Seok ^a   Jang, Geundoo ^a   Kim, Eun Kyoung ^a   Kang, Byung Woog ^a   Kim, Chul ^a   Kim, Jeong Eun ^a   Kim, Shin ^a   Lee, Dae Ho ^a   Lee, Jung Shin ^a   Park, Seo Jin ^a   Park, Chan Jeoung ^a   Huh, Jooryung ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD34 SELECTION; EVENT FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE RECOVERY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69249163801     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02202.x     Document Type: Article

References (41)

1. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Moreb JS. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003 31 : 1009 13.
2. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002 117 : 629 33.
3. Kim H, Sohn HJ, Kim SE, Kang HJ, Park S, Kim S, Kim WK, Lee JS, Suh C. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 34 : 43 9.
4. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001 98 : 579 85.
5. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006 37 : 1037 42.
6. Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006 37 : 865 71.
7. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008 14 : 807 16.
8. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004 33 : 291 8.
9. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004 18 : 1085 92.
10. Porrata LF, Gastineau DA, Padley D, Bundy K, Markovic SN. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003 44 : 997 1000.
11. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008 14 : 116 24.
12. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M, Vazquez L, López-Berges C, Cañizo MC, Mateos MV, Orfao A, San Miguel JF. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 24 : 1279 83.
13. Weaver CH, Potz J, Redmond J, Tauer K, Schwartzberg LS, Kaywin P, Drapkin R, Grant B, Unger P, Allen C, Longin K, Zhen B, Hazelton B, Buckner CD. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone Marrow Transplant 1997 19 : 1103 10.
14. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995 86 : 3961 9.
15. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard EM, Bouafia F, Coiffier B. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998 91 : 3148 55.
16. Ringden O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA, Litzow MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003 121 : 874 85.
17. Nakamura R, Auayporn N, Smith DD, Palmer J, Sun JY, Schriber J, Pullarkat V, Parker P, Rodriguez R, Stein A, Rosenthal J, Wang S, Karanas C, Gaal K, Senitzer D, Forman SJ. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008 14 : 449 57.
18. Bittencourt H, Rocha V, Chevret S, Socié G, Espérou H, Devergie A, Dal Cortivo L, Marolleau JP, Garnier F, Ribaud P, Gluckman E. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002 99 : 2726 33.
19. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996 88 : 3223 9.
20. Dominietto A, Lamparelli T, Raiola AM, Van Lint MT, Gualandi F, Berisso G, Bregante S, Di Grazia C, Soracco M, Pitto A, Frassoni F, Bacigalupo A. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002 100 : 3930 4.
21. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997 89 : 4226 35.
22. Perez-Simon JA, Diez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C, Brunet S, Altes A, Vazquez L, Sierra J, Miguel JF. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003 102 : 1108 13.
23. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon : IARC Press 2001.
24. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971 31 : 1860 1.
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 94.
26. Suh C, Kim S, Kim SH, Kim EK, Lee JL, Park KU, Park JS, Lee J, Kim MW, Chi HS, Park CJ, Kim SW. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004 44 : 1762 8.
27. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005 35 : 449 54.
28. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996 5 : 213 26.
29. Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007 40 : 919 24.
30. Kang BW, Jo J-C, Kim S, Jang G, Lee SS, Sym SJ, Ryu J-S, Kim WS, Yoon SS, Suh C. Multicenter phase II trial of 90Y-Ibritumomab Tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL. ASH Annual Meeting Abstracts 2007 110 : 1914.
31. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 25 : 579 86.
32. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R, Dunbar CE, Gress R, Altemus R, Young NS, Barrett AJ. Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001 115 : 95 104.
33. Blystad AK, Delabie J, Kvaloy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004 125 : 605 12.
34. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006 37 : 731 7.
35. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, Chaudhry A, Brown C, Gluck S, Russell JA. A low CD34+ cell dose predicts relapse and death early following autologous blood stem cell transplantation. Hematology 2001 6 : 19 27.
36. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998 92 : 1471 90.
37. Perez-Simon JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, Amigo ML, Berges C, González M, Del Cañizo C, San Miguel JF. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998 38 : 385 91.
38. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995 13 : 2547 55.
39. Kiss JE, Rybka WB, Winkelstein A, deMagalhaes-Silverman M, Lister J, D'Andrea P, Ball ED. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997 19 : 303 10.
40. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, Chaudhry A, Brown C, Russell JA, Gluck S. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose. Bone Marrow Transplant 2000 25 : 435 40.
41. Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001 28 : 865 71.